SGLT2-i exhibited a consistent benefit of the reduction in CI-AKI across different patients’ comorbidity and indications to undergo invasive procedures with ICM suggesting its protection in all spectra of HF patients, with no differences based on the presence of pre-existing chronic kidney disease and/or diabetes, as already demonstrated in previous investigations [15]. Here, SLC5A2 is linked to diabetes mellitus.